FDA Approves Trodelvy for First-Line Treatment of Metastatic TNBC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- FDA Approval for New Indication: Gilead Sciences announced that its cancer drug Trodelvy has received FDA approval for first-line treatment of metastatic triple-negative breast cancer (mTNBC), marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Data Support: The FDA approval is based on data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, demonstrating that Trodelvy monotherapy reduces the risk of disease progression or death by 38%, while its combination with Keytruda lowers this risk by 35%, indicating substantial clinical efficacy.
- Significant Market Potential: With mTNBC accounting for approximately 15% of all breast cancers and a five-year survival rate of only 12%, the approval of Trodelvy provides a new treatment option for this high-risk patient population, which is expected to drive future sales growth for the company.
- Sales Growth Trend: GILD's Trodelvy achieved sales of $1.40 billion in 2025, a 6% increase from $1.32 billion the previous year, reflecting strong market performance and sustained demand for the drug, further solidifying Gilead's position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 125.050
Low
105.00
Averages
137.88
High
154.00
Current: 125.050
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trodelvy Approved by FDA for First-Line mTNBC Treatment
- FDA Approval: Trodelvy (sacituzumab govitecan-hziy) has received FDA approval as the first Trop-2-directed antibody-drug conjugate (ADC) for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), marking a significant advancement in treatment options for patients.
- Clinical Trial Support: Based on the ASCENT-03 and ASCENT-04 studies, Trodelvy monotherapy reduced the risk of disease progression or death by 38% in PD-L1 negative patients, and by 35% when combined with Keytruda in PD-L1 positive patients, demonstrating substantial clinical benefits.
- Broad Patient Impact: With over 75,000 breast cancer patients treated globally, Trodelvy stands as the only Trop-2-directed ADC to show meaningful overall survival benefits in both second-line or later mTNBC and pre-treated HR+/HER2- metastatic breast cancer, enhancing patient survival and quality of life.
- Establishment of New Standard: The NCCN has recommended Trodelvy with or without Keytruda as a preferred first-line treatment option for mTNBC, reflecting its significance in clinical practice and expected to transform treatment choices and outcomes for patients.
See More
FDA Approves Trodelvy for First-Line Treatment of Metastatic TNBC
- FDA Approval for New Indication: Gilead Sciences announced that its cancer drug Trodelvy has received FDA approval for first-line treatment of metastatic triple-negative breast cancer (mTNBC), marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Data Support: The FDA approval is based on data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, demonstrating that Trodelvy monotherapy reduces the risk of disease progression or death by 38%, while its combination with Keytruda lowers this risk by 35%, indicating substantial clinical efficacy.
- Significant Market Potential: With mTNBC accounting for approximately 15% of all breast cancers and a five-year survival rate of only 12%, the approval of Trodelvy provides a new treatment option for this high-risk patient population, which is expected to drive future sales growth for the company.
- Sales Growth Trend: GILD's Trodelvy achieved sales of $1.40 billion in 2025, a 6% increase from $1.32 billion the previous year, reflecting strong market performance and sustained demand for the drug, further solidifying Gilead's position in the biopharmaceutical sector.
See More
QQQ ETF Outperforms S&P 500 Over Last Decade
- Outstanding Historical Performance: Over the past decade, the Invesco QQQ Trust ETF has achieved a return of 570%, significantly outperforming the S&P 500's 255%, highlighting its strong appeal among investors, particularly driven by tech stocks.
- Diversified Portfolio: While QQQ is tech-heavy (66.9%), it also includes non-tech companies like Walmart and Costco, ensuring that other sectors can provide support during tech industry fluctuations, thereby enhancing investment stability.
- AI Boom Contribution: Much of QQQ's strong performance is attributed to the current AI boom, with nine of its component companies valued at over $1 trillion, driving overall valuation increases and further solidifying its market leadership.
- Confidence in Future Growth: Despite high valuations in tech stocks, the diverse growth opportunities of QQQ's holdings, such as cloud computing and biotech, instill confidence in investors for continued outperformance over the next decade.
See More
FDA Approves Trodelvy for First-Line Treatment of Triple-Negative Breast Cancer
- FDA Approval: Gilead Sciences announced that its drug Trodelvy has received FDA approval as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, marking a significant advancement in cancer therapy.
- Clinical Trial Support: Data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 studies indicate that Trodelvy monotherapy reduces the risk of disease progression or death by 38% in patients ineligible for PD-L1 inhibitors, demonstrating substantial efficacy.
- Combination Therapy Benefits: In the ASCENT-04 study, the combination of Trodelvy and Keytruda reduced the risk of disease progression or death by 35% in PD-L1-positive patients, further solidifying its position in treatment protocols.
- Preferred Treatment Status: The National Comprehensive Cancer Network (NCCN) lists Trodelvy as a preferred first-line treatment option for mTNBC, and it is approved in over 60 countries for second-line or later metastatic triple-negative breast cancer, highlighting its global recognition and application potential.
See More
QQQ ETF Outperforms S&P 500 with Strong Tech Growth
- Significant Returns: The Invesco QQQ Trust ETF has achieved a remarkable 570% return over the past decade, significantly outperforming the S&P 500's 255%, indicating its strong appeal among investors and attracting more capital inflow.
- Tech Sector Dominance: With tech stocks comprising 66.9% of QQQ, the 'Magnificent Seven' including Nvidia and Apple account for nearly 35% of the ETF, highlighting QQQ's heavy reliance on tech growth while providing support from other sectors.
- AI Boom Driving Growth: The current AI surge has propelled nine component companies of QQQ to valuations exceeding $1 trillion, reflecting the strong performance of tech stocks that drive QQQ, although high valuations may pose risks of pullbacks.
- Diverse Investment Opportunities: QQQ is not solely dependent on the tech sector, encompassing various fields such as cloud computing and biotech, and while future annual returns may not reach 21%, it is expected to continue outperforming other investment options in the market.
See More
Gilead's Trodelvy Approved by FDA for Triple-Negative Breast Cancer
- FDA Approval: Gilead's Trodelvy (sacituzumab govitecan) has received FDA approval as a first-line treatment for triple-negative breast cancer, both as a monotherapy and in combination with Merck's Keytruda (pembrolizumab), highlighting its significant clinical value.
- Clinical Trial Support: The monotherapy indication was granted based on results from the ASCENT-03 trial, while the combination indication was supported by ASCENT-04/KEYNOTE D-19, demonstrating Trodelvy's reliability and efficacy in treatment outcomes.
- Expanded Indications: Trodelvy is also approved for HR+/HER- metastatic breast cancer, further broadening its market application and enhancing Gilead's competitive position in the breast cancer treatment landscape.
- Market Potential: With FDA approval, Trodelvy's market prospects are viewed positively, and analysts believe Gilead's growth potential is underestimated, which could drive an increase in the company's stock price.
See More
Trodelvy Approved by FDA for First-Line mTNBC Treatment
- FDA Approval: Trodelvy (sacituzumab govitecan-hziy) has received FDA approval as the first Trop-2-directed antibody-drug conjugate (ADC) for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), marking a significant advancement in treatment options for patients.
- Clinical Trial Support: Based on the ASCENT-03 and ASCENT-04 studies, Trodelvy monotherapy reduced the risk of disease progression or death by 38% in PD-L1 negative patients, and by 35% when combined with Keytruda in PD-L1 positive patients, demonstrating substantial clinical benefits.
- Broad Patient Impact: With over 75,000 breast cancer patients treated globally, Trodelvy stands as the only Trop-2-directed ADC to show meaningful overall survival benefits in both second-line or later mTNBC and pre-treated HR+/HER2- metastatic breast cancer, enhancing patient survival and quality of life.
- Establishment of New Standard: The NCCN has recommended Trodelvy with or without Keytruda as a preferred first-line treatment option for mTNBC, reflecting its significance in clinical practice and expected to transform treatment choices and outcomes for patients.
See More
FDA Approves Trodelvy for First-Line Treatment of Metastatic TNBC
- FDA Approval for New Indication: Gilead Sciences announced that its cancer drug Trodelvy has received FDA approval for first-line treatment of metastatic triple-negative breast cancer (mTNBC), marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Data Support: The FDA approval is based on data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, demonstrating that Trodelvy monotherapy reduces the risk of disease progression or death by 38%, while its combination with Keytruda lowers this risk by 35%, indicating substantial clinical efficacy.
- Significant Market Potential: With mTNBC accounting for approximately 15% of all breast cancers and a five-year survival rate of only 12%, the approval of Trodelvy provides a new treatment option for this high-risk patient population, which is expected to drive future sales growth for the company.
- Sales Growth Trend: GILD's Trodelvy achieved sales of $1.40 billion in 2025, a 6% increase from $1.32 billion the previous year, reflecting strong market performance and sustained demand for the drug, further solidifying Gilead's position in the biopharmaceutical sector.
See More
QQQ ETF Outperforms S&P 500 Over Last Decade
- Outstanding Historical Performance: Over the past decade, the Invesco QQQ Trust ETF has achieved a return of 570%, significantly outperforming the S&P 500's 255%, highlighting its strong appeal among investors, particularly driven by tech stocks.
- Diversified Portfolio: While QQQ is tech-heavy (66.9%), it also includes non-tech companies like Walmart and Costco, ensuring that other sectors can provide support during tech industry fluctuations, thereby enhancing investment stability.
- AI Boom Contribution: Much of QQQ's strong performance is attributed to the current AI boom, with nine of its component companies valued at over $1 trillion, driving overall valuation increases and further solidifying its market leadership.
- Confidence in Future Growth: Despite high valuations in tech stocks, the diverse growth opportunities of QQQ's holdings, such as cloud computing and biotech, instill confidence in investors for continued outperformance over the next decade.
See More
FDA Approves Trodelvy for First-Line Treatment of Triple-Negative Breast Cancer
- FDA Approval: Gilead Sciences announced that its drug Trodelvy has received FDA approval as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, marking a significant advancement in cancer therapy.
- Clinical Trial Support: Data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 studies indicate that Trodelvy monotherapy reduces the risk of disease progression or death by 38% in patients ineligible for PD-L1 inhibitors, demonstrating substantial efficacy.
- Combination Therapy Benefits: In the ASCENT-04 study, the combination of Trodelvy and Keytruda reduced the risk of disease progression or death by 35% in PD-L1-positive patients, further solidifying its position in treatment protocols.
- Preferred Treatment Status: The National Comprehensive Cancer Network (NCCN) lists Trodelvy as a preferred first-line treatment option for mTNBC, and it is approved in over 60 countries for second-line or later metastatic triple-negative breast cancer, highlighting its global recognition and application potential.
See More
QQQ ETF Outperforms S&P 500 with Strong Tech Growth
- Significant Returns: The Invesco QQQ Trust ETF has achieved a remarkable 570% return over the past decade, significantly outperforming the S&P 500's 255%, indicating its strong appeal among investors and attracting more capital inflow.
- Tech Sector Dominance: With tech stocks comprising 66.9% of QQQ, the 'Magnificent Seven' including Nvidia and Apple account for nearly 35% of the ETF, highlighting QQQ's heavy reliance on tech growth while providing support from other sectors.
- AI Boom Driving Growth: The current AI surge has propelled nine component companies of QQQ to valuations exceeding $1 trillion, reflecting the strong performance of tech stocks that drive QQQ, although high valuations may pose risks of pullbacks.
- Diverse Investment Opportunities: QQQ is not solely dependent on the tech sector, encompassing various fields such as cloud computing and biotech, and while future annual returns may not reach 21%, it is expected to continue outperforming other investment options in the market.
See More
Gilead's Trodelvy Approved by FDA for Triple-Negative Breast Cancer
- FDA Approval: Gilead's Trodelvy (sacituzumab govitecan) has received FDA approval as a first-line treatment for triple-negative breast cancer, both as a monotherapy and in combination with Merck's Keytruda (pembrolizumab), highlighting its significant clinical value.
- Clinical Trial Support: The monotherapy indication was granted based on results from the ASCENT-03 trial, while the combination indication was supported by ASCENT-04/KEYNOTE D-19, demonstrating Trodelvy's reliability and efficacy in treatment outcomes.
- Expanded Indications: Trodelvy is also approved for HR+/HER- metastatic breast cancer, further broadening its market application and enhancing Gilead's competitive position in the breast cancer treatment landscape.
- Market Potential: With FDA approval, Trodelvy's market prospects are viewed positively, and analysts believe Gilead's growth potential is underestimated, which could drive an increase in the company's stock price.
See More
